Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1954 1
1964 2
1971 1
1973 1
1974 1
1979 2
1980 1
1983 1
1984 3
1985 3
1988 1
1991 1
1993 1
1994 1
1995 2
1996 3
1997 3
1998 3
1999 4
2000 5
2001 3
2002 3
2003 8
2004 3
2005 3
2006 5
2007 3
2008 3
2009 4
2010 5
2011 19
2012 15
2013 10
2014 6
2015 9
2016 11
2017 13
2018 16
2019 18
2020 18
2021 15
2022 9
Text availability
Article attribute
Article type
Publication date

Search Results

217 results
Results by year
Filters applied: . Clear all
Page 1
Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study.
Solomon BJ, Besse B, Bauer TM, Felip E, Soo RA, Camidge DR, Chiari R, Bearz A, Lin CC, Gadgeel SM, Riely GJ, Tan EH, Seto T, James LP, Clancy JS, Abbattista A, Martini JF, Chen J, Peltz G, Thurm H, Ou SI, Shaw AT. Solomon BJ, et al. Among authors: james lp. Lancet Oncol. 2018 Dec;19(12):1654-1667. doi: 10.1016/S1470-2045(18)30649-1. Epub 2018 Nov 6. Lancet Oncol. 2018. PMID: 30413378 Clinical Trial.
Resensitization to Crizotinib by the Lorlatinib ALK Resistance Mutation L1198F.
Shaw AT, Friboulet L, Leshchiner I, Gainor JF, Bergqvist S, Brooun A, Burke BJ, Deng YL, Liu W, Dardaei L, Frias RL, Schultz KR, Logan J, James LP, Smeal T, Timofeevski S, Katayama R, Iafrate AJ, Le L, McTigue M, Getz G, Johnson TW, Engelman JA. Shaw AT, et al. Among authors: james lp. N Engl J Med. 2016 Jan 7;374(1):54-61. doi: 10.1056/NEJMoa1508887. Epub 2015 Dec 23. N Engl J Med. 2016. PMID: 26698910 Free PMC article. Clinical Trial.
Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial.
Shaw AT, Felip E, Bauer TM, Besse B, Navarro A, Postel-Vinay S, Gainor JF, Johnson M, Dietrich J, James LP, Clancy JS, Chen J, Martini JF, Abbattista A, Solomon BJ. Shaw AT, et al. Among authors: james lp. Lancet Oncol. 2017 Dec;18(12):1590-1599. doi: 10.1016/S1470-2045(17)30680-0. Epub 2017 Oct 23. Lancet Oncol. 2017. PMID: 29074098 Free PMC article. Clinical Trial.
Perceived Barriers to COVID-19 Testing.
McElfish PA, Purvis R, James LP, Willis DE, Andersen JA. McElfish PA, et al. Among authors: james lp. Int J Environ Res Public Health. 2021 Feb 25;18(5):2278. doi: 10.3390/ijerph18052278. Int J Environ Res Public Health. 2021. PMID: 33668958 Free PMC article.
Arkansans' Preferred COVID-19 Testing Locations.
McElfish PA, Willis DE, Bryant-Moore K, Rojo MO, Andersen JA, Kaminicki KF, James LP. McElfish PA, et al. Among authors: james lp. J Prim Care Community Health. 2021 Jan-Dec;12:21501327211004289. doi: 10.1177/21501327211004289. J Prim Care Community Health. 2021. PMID: 33771056 Free PMC article.
Dimensionality Reduction for Countermovement Jump Metrics.
James LP, Suppiah H, McGuigan MR, Carey DL. James LP, et al. Int J Sports Physiol Perform. 2021 Jul 1;16(7):1052-1055. doi: 10.1123/ijspp.2020-0606. Epub 2021 Mar 1. Int J Sports Physiol Perform. 2021. PMID: 33647877
Acetaminophen-induced hepatotoxicity.
James LP, Mayeux PR, Hinson JA. James LP, et al. Drug Metab Dispos. 2003 Dec;31(12):1499-506. doi: 10.1124/dmd.31.12.1499. Drug Metab Dispos. 2003. PMID: 14625346 Review.
217 results